Annovis Bio (NYSE: ANVS) announced the promotion of Cheng Fang, Ph.D., to chief scientific officer, effective immediately. Dr. Fang, who joined the company in 2021 and most recently served as senior vice president of research and development, will oversee scientific strategy and research operations across Annovis’ Alzheimer’s disease (AD) and Parkinson’s disease (PD) programs. His responsibilities include translational science, clinical development, biomarker strategy and regulatory interactions.
The promotion comes at a critical juncture for Annovis as it advances its lead drug candidate, buntanetap, toward top-line data from its pivotal Phase 3 Alzheimer’s disease study and a subsequent New Drug Application (NDA) submission. According to the company, Dr. Fang has played a key role in advancing the company’s clinical development efforts and will lead its scientific strategy through upcoming clinical and regulatory milestones. The full press release is available at https://ibn.fm/c9jdt.
Annovis Bio is a Phase 3 clinical-stage biotechnology company headquartered in Malvern, Pennsylvania, focusing on treatments for neurodegenerative diseases. Its lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients.
Dr. Fang’s promotion signals Annovis’ commitment to strengthening its leadership as it nears critical data readouts. The company’s progress with buntanetap is closely watched by investors and the medical community, given the high unmet need in Alzheimer’s and Parkinson’s diseases. For more information about Annovis, visit https://www.annovisbio.com and follow on LinkedIn, YouTube, and X. The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS.
